In this publication, we review the past year and discuss our outlook for the next 12 months. We begin our discussion with the macro factors at play, including GDP forecasts, the geopolitical landscape and our expectations for cost inflation. We also trace the development of primary markets in the European HY space, and give our view on defaults in general as well as for our coverage universe. We then discuss sector trends and expectations, along with earnings development for companies under our ...
Notre 28ième Forum vient de se dérouler (9 et 10 janvier) à Lyon. Il a réuni 207 sociétés, originaire à ~47% de France, à 26% d’Allemagne et 28% du reste de l’Europe. L’édition 2025 de notre Forum a accueilli 481 investisseurs (dont 64% français), travaillant pour 206 institutions de 15 pays. Nous avons ainsi organisé l’équivalent de 5 258 investors meetings dont 287 portant uniquement sur la RSE ou l’ESG. Ce document synthétise nos feed-back concernant les émetteurs obligataires présents.
Our 28th Forum has just taken place (9 and 10 January) in Lyon. It was attended by 207 companies, ~47% from France, 26% from Germany and 28% from the rest of Europe. The 2025 edition of our Forum welcomed 481 investors (64% of whom were French), working for 206 institutions in 15 countries. We organised the equivalent of 5,258 investor meetings, 287 of which related solely to CSR and ESG. This document summarizes our feedback on the bond issuers attending this forum.
We are hosting our 28th ODDO BHF Forum in Lyon on 9 and 10 January 2025. In total, 211 companies will be presenting over the two days. In the following note, we provide some initial feedback from the companies on day 1. Out of the 104 feedbacks collected during the first day, 40 were clearly positive, 59 rather Neutral, and only 6 negative. Among the positive names, we would particularly highlight Accor, URW, Euronext, Bureau Veritas, Renke, ID Logistics, Roche Bobois, Ionos, Companie des Alpes...
Grifols: the board considers that Brookfield’s indicative price undervalues the company Teva: S&P upgrades the rating to BB/positive from BB/positiveElior: Results recovered in 2023-24, exceeding expectations. Debt reduction is making headway as planned.Tereos: Sharp decline in EBITDA in Q2 24/25. The financial position is stable thanks to the generation of FCF.>...
Grifols : le conseil d’administration estime que le prix indicatif proposé par Brookfield sous-évalue la sociétéTeva: S&P upgrades the rating to BB/positive from BB/positiveElior: les résultats se sont redressés 2023/24, dépassant les attentes. Le désendettement progresse comme prévu.Tereos : fort repli de l'EBITDA au T2 24/25. La situation financière est stable grâce à la génération de FCF.>...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.